AI assistant
SOLIS MINERALS LIMITED — Capital/Financing Update 2021
Dec 21, 2021
65813_rns_2021-12-21_de6e7602-14de-4fdb-bc66-83d64c10f99b.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
595 Burrard Street, Suite 3043, Vancouver B.C, V7X 1L7
==> picture [133 x 45] intentionally omitted <==
ASX RELEASE
24 December 2021 Market Announcements Platform ASX Limited
UPDATED STATEMENT OF COMMITMENTS
The below table sets out the statement of commitments based on the actual amount of funds raised, being $5,500,000.
| Use of funds | $5,500,000Subscription (A$) | $5,500,000Subscription (A$) |
|---|---|---|
| Exploration programs - Mostazal (Chile)1 | 1,908,986 | 27.2% |
| Exploration program - Ilo Este and Ilo Norte (Peru)2 | 235,600 | 3.4% |
| Mostazal Option Payments3 | 1,662,050 | 23.7% |
| Costs of the Offer4 | 820,474 | 11.7% |
| Corporate Costs and general Working Capital5 | 2,381,245 | 34.0% |
| TOTAL | 7,008,355 | 100% |
Notes :
-
Mostazal Project ( Chile ) - The drilling and exploration program for the Mostazal Project as set out in Section 2.3 of the Prospectus dated 10 November 2021 for the Maximum Subscription Scenario of $6,000,000, has been adjusted downward as follows:
-
a. the allocation of funds of A$2,359,732 has been adjusted to a final allocation of A$1,908,986;
-
b. Phase II exploration activities will be reduced from an estimated 1,950m of HQ drilling to 950m of HQ drilling, with Phase II drilling remaining contingent on assay results from Phase I drilling and favourable geological observations; and
-
c. The Company has a current contract for up to 3,000m of drilling which is sufficient to cover the revised Phase I and Phase II drilling totals of 2,900m.
-
-
Ilo Este and Ilo Norte ( Peru ) - There has been no change to the funds allocated to these projects.
-
No change.
-
Offer Costs with a variable component (including TSX-V fees, ASX fees and Lead Manager fees) have been adjusted on the basis of funds raised of $5,500,000.
-
No change.
Authorised for release by the Directors of the Company. Ends
Doc ID 906821193/v1 Doc ID 906821193/v1